ArticleClinical pharmacology and therapeutics2019
The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction.
Article in Clinical pharmacology and therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Predictive Safety in the Era of Artificial Intelligence: Promises, Limits, and the Case for an Enterprise Lifecycle Evidence Ecosystem.Drug safety · 2026Review
- The rhythm of decline: Circadian disruption in neurodegeneration.Journal of food and drug analysis · 2025Review
- Multilevel and multimodal biobehavioral methods in the study of stress, trauma, and resilience: a systems approach.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Expanding scope of genetic studies in the era of biobanks.Human molecular genetics · 2025Article
- Knowledge map of programmed cell death in esophageal cancer: a bibliometric analysis.Discover oncology · 2025Article
- Current Trends in the Biomarker's Discovery for the Treatment and Management of Colorectal Cancer: A Comprehensive Review.Current medicinal chemistry · 2025Review
- Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.Journal of clinical and translational science · 2024Review
- Evaluation of biological markers for the risk assessment of carbon black in epidemiological studies.Frontiers in public health · 2024Review
- Biomarkers in osteoarthritis: current status and outlook - the FNIH Biomarkers Consortium PROGRESS OA study.Skeletal radiology · 2023Review
- Clinical Utility of Fluid Biomarker in Depressive Disorder.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2022Review
- Accelerating therapeutic discoveries for heart failure: a new public-private partnership.Nature reviews. Drug discovery · 2022Article
- The Pivotal Role of Quantum Dots-Based Biomarkers Integrated with Ultra-Sensitive Probes for Multiplex Detection of Human Viral Infections.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Exercise and Nutrition Strategies for Combating Sarcopenia and Type 2 Diabetes Mellitus in Older Adults.Journal of functional morphology and kinesiology · 2022Review
- Human disease biomarker panels through systems biology.Biophysical reviews · 2021Review
- Imaging and Biochemical Markers for Osteoarthritis.Diagnostics (Basel, Switzerland) · 2021Article
- Liquid biopsy enters the clinic - implementation issues and future challenges.Nature reviews. Clinical oncology · 2021Review
- Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools.Archives of toxicology · 2021Review
- Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience.Clinical and translational science · 2021Review
- The Yin and the Yang of Transformative Research During the COVID-19 Pandemic-A Perspective.Frontiers in pediatrics · 2021Article
- Novel Approaches for Assessing Circadian Rhythmicity in Humans: A Review.Journal of biological rhythms · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) is a public-private partnership that aims to facilitate drug development with biomarkers across a range of therapeutic areas. The BC is organized to address specific precompetitive biomarker projects, giving participating stakeholders a role in the design and conduct of projects and making the results freely public. Ultimately, the goals of the BC are to accelerate the development of new medicines, inform regulatory decision making, and improve patient care. Here, we describe how the BC works and briefly highlight its accomplishments. The BC has had many notable successful biomarker projects in the past 12 years, including I-SPY2, which has improved clinical trials and biomarker use for breast cancer, and an evidentiary framework for biomarker qualification. Recently, the BC has undergone a strategic expansion of its scope to include related drug development tools along the lines of the Biomarkers, Endpoints, and other Tools (BEST) resource.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.